atrasentan has been researched along with Malignant Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agharazii, M; Bélanger, S; Larivière, R; Lebel, M; Lemieux, P; Therrien, F | 1 |
| Blezer, EL; Goldschmeding, R; Jansen, GH; Joles, JA; Koomans, HA; Nicolay, K; Rabelink, TJ | 1 |
2 other study(ies) available for atrasentan and Malignant Hypertension
| Article | Year |
|---|---|
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Endothelin-1; Hydralazine; Hypertension, Malignant; Losartan; Male; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renal Insufficiency | 2009 |
Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats.
Topics: Animals; Atrasentan; Blood Pressure; Brain Edema; Data Interpretation, Statistical; Endothelin Receptor Antagonists; Hypertension; Hypertension, Malignant; Kidney; Magnetic Resonance Imaging; Male; Proteinuria; Pyrrolidines; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Stereoisomerism; Time Factors | 1999 |